Atlas market file · Equity · United States
Nano-X Imaging Ltd.NNOX
- Last close
- 1.06
- Change
- +3.92%
- 96-bar range
- 0.734 – 3.06
- As of
- 7 Aug 2026
Nano-X Imaging Ltd. is a x-ray apparatus & tubes & related irradiation apparatus issuer listed as NNOX on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
NNOX
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-84.94% over the window).
Source rail: Yahoo Finance chart API (NNOX). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for NNOX. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
NNOX public profile
X-ray apparatus & tubes & related irradiation apparatus issuer. Nano-X Imaging Ltd. is connected to current market context, cited company sources and its retained research file.
Nano-X Imaging Ltd. trades as NNOX on NASDAQ. Nano-X Imaging Ltd. (NNOX) has a latest verified close of 1.06, up 3.92%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files NNOX under USA Stocks for browsing.
What changed for Nano-X Imaging Ltd. today
Nano-X Imaging Ltd. (NNOX) closed 2026-07-28 with its usual blend of technological optimism and financial gravity. The company’s recent 424B5 filing highlighted ongoing efforts to commercialize its Nanox System, a medical imaging platform designed to democratize diagnostic scanning-but not before warning that payors like CMS could deny reimbursement for its services under the Appropriate Use Criteria program. This tension between grand vision and reimbursement reality sits atop financials showing $13.0M in 2025 revenue against a $75.0M net loss, with operating cash flow negative $40.8M for the year.
The company’s core business revolves around the Nanox System, which combines AI-driven imaging with a subscription model. However, the 20-F filing reveals a business still deep in the proof-of-concept phase: inventory sits at $3.1M, R&D costs consumed 147% of revenue, and stockholders’ equity ($139.7M) is propped up by $49.2M in cash-most of which is being spent faster than a startup founder at a WeWork happy hour. The 6-K filings from July 23, 2026, added little new information beyond 'preliminary updates,' leaving investors to wonder if the company’s main product is data or delay.
Chartwise, NNOX remains a speculative microcap with thin liquidity and no clear technical support level mentioned in the evidence. The shares have diluted 64,790,000 outstanding, per the 20-F, and recent insider transactions (see 4 filing, June 15, 2026) show executives more focused on share issuance than buybacks. The company’s ability to survive hinges on extending its cash runway or securing partnerships-a catalyst that remains as uncertain as the AUC criteria governing its reimbursement fate.
Risks include regulatory pushback on imaging reimbursement, rapid cash depletion ($49.2M cash vs. $40.8M annual burn), and dilution from ongoing share issuances. On the positive side, CMS approval for broader AUC coverage or a major hospital partnership could shift the narrative. Until then, NNOX is a case study in how much money one can lose while trying to revolutionize healthcare.
Sources & evidence · 9 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
NNOX technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on NNOX
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep NNOX research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
NNOX FAQ
What is Nano-X Imaging Ltd. (NNOX)?Nano-X Imaging Ltd. (NNOX) has a latest verified close of 1.06, up 3.92%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed...
Nano-X Imaging Ltd. (NNOX) has a latest verified close of 1.06, up 3.92%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for NNOX?Nano-X Imaging Ltd. (NNOX) has a latest verified close of 1.06, up 3.92%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks...
Nano-X Imaging Ltd. (NNOX) has a latest verified close of 1.06, up 3.92%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files NNOX under USA Stocks for browsing.
How often is the NNOX page updated?The NNOX public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The NNOX public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for NNOX?The NNOX file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:NNOX. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The NNOX file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:NNOX. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on NNOX?Yes. The workstation can open NNOX, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open NNOX, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this NNOX page investment advice?No. The NNOX page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The NNOX page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →